Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastrointest Endosc. Jan 16, 2014; 6(1): 13-19
Published online Jan 16, 2014. doi: 10.4253/wjge.v6.i1.13
Published online Jan 16, 2014. doi: 10.4253/wjge.v6.i1.13
Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction
Andrea Oliver Tal, Johannes Vermehren, Mireen Friedrich-Rust, Jörg Bojunga, Christoph Sarrazin, Stefan Zeuzem, Jörg Trojan, Jörg Gerhard Albert, Medizinische Klinik 1, Universitätsklinikum Frankfurt, 60590 Frankfurt am Main, Germany
Author contributions: Tal AO and Albert JG designed and performed the research; Friedrich-Rust M, Bojunga J, Sarrazin C, Trojan J and Albert JG performed the interventions and obtained clinical data; Tal AO, Vermehren J, Zeuzem S and Albert JG analyzed the data and wrote the paper.
Correspondence to: Jörg Gerhard Albert, MD, Medizinische Klinik 1, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. j.albert@med.uni-frankfurt.de
Telephone: +49-69-63015297 Fax: +49-69-63016247
Received: September 4, 2013
Revised: November 11, 2013
Accepted: December 9, 2013
Published online: January 16, 2014
Processing time: 134 Days and 1.1 Hours
Revised: November 11, 2013
Accepted: December 9, 2013
Published online: January 16, 2014
Processing time: 134 Days and 1.1 Hours
Core Tip
Core tip: Radiofrequency ablation (RFA) is a promising tool for the treatment of patients with perihilar and intrahepatic bile duct cancer. While RFA is easy to perform and technical success rates are high, the outcome of patients remains unclear. Therefore, the long-term efficacy of this treatment approach needs to be studied in randomized trials.